OncoTargets and Therapy (Mar 2022)
The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma
Abstract
Han-yu Jiang,1,* Hui-min Zheng,1,* Cheng Xia,1 Xiang Li,1 Gang Wang,1 Tong Zhao,1 Xiao-nan Cui,2 Ruo-yu Wang,1,3 Ying Liu1,3 1Department of Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, People’s Republic of China; 2Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, 116011, People’s Republic of China; 3The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Dalian, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying Liu, Department of Oncology, The Affiliated Zhongshan Hospital of Dalian University, Dalian, People’s Republic of China, Tel +8615942653462, Fax +86 411-62893555 Email [email protected] Ruo-yu Wang, Department of Oncology, The Affiliated Zhongshan Hospital of Dalian University, No. 6, Liberation Street, Zhongshan District, Dalian, 116001, People’s Republic of China, Tel +86071762897187, Fax +86 411-62893555, Email [email protected]: Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world with a five-year survival rate of less than 20%. Nonetheless, selecting an appropriate therapeutic agent to inhibit the development of hepatoma cells is still a challenge. Bufalin, a component of the traditional Chinese medicine Chansu, has been shown to inhibit the proliferation, invasion and metastasis of HCC through various signaling pathways. In addition, bufalin and sorafenib demonstrate a synergistic effect in cancer therapeutics. This review highlighted on several focal signaling pathways involved in the inhibitory effects of bufalin on HCC and its synergistic mechanisms with sorafenib. The immunotherapy effect of bufalin has also been discussed as a novel property.Keywords: bufalin, cancer, therapy, signaling pathways, immunotherapy effect
